

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

and BD should be printed. printed. \$4.9.03 PRADEMARY

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Carlos Plata-Salaman
Group Art Unit	1623
Examiner Name	FONDA
Attorney Docket Number	ORT-1453

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
XIGE	- A /	OSBORNE et a Doplamate Improves Rivcemic Control and Triglycerides in Animal Models. Presented to ADA. Abstracts published on hitp://www.biabeles.outramouAnneameeting/Abstracts/AbstractSearch.asp pp 1-11 Abstract.	\ \
	34	published of Nine http://www.diabetes.oug/apro1/Annfar/Meeting/Abstracts/AbstractSearch.asp.pp 1-11 Abstract.	
KKE	BB	OSBORNE Figures 4 pages June 2001, presented to ADA.	
CICE		DEMAREST, K. E. All Topingmate Improves Tolefance and May Improve Insulin-Sensitivity in Animal Models of Type 2.  Diabetes Melitus. Pages 1-10 Abstract	
	BO A	DEMAREST POSTER 6 PAGES Figure 1a to Figure 4 June 2001, presented to ADA.	<u> </u>
KKF	20 1	CROOKED LANGESTRUCTED OPERIOR TO THE INTERIOR SOLVENIES CONTROLLED TO THE CONTROLLED	
	130	DEMAREST ET AL ABSTRACT Topirmate Improves Glucose Tolerance and May Improve Insulin Sensitivity in Annual	
100	BE.	Models of Type 2 Diabetes Methods 1 page	
66	De-	OSBORNEET AL ABSTRACT Topiramete Improves Glycemic Control and Tighycerides in Animal Models Topical	
	· · · · · ·		50,
		-	
	ļ .		<u> </u>
		·	
			<b>-</b>
<del></del>			
	<del> </del>		
	-		
	<u> </u>		
	<u> </u>		<b></b>
	<u> </u>		-
	<del> </del>		<del> </del>
	<del>                                     </del>		

Examiner Signature	RR Onda	Date Considered	3-18-03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

Application Number

09/900,567

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	Valid OIVID COITEOFTIUTIDEL.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Carlos Plata-Salaman
Group Art Unit	1623
Examiner Name	FONDA
Attorney Docket Number	ORT-1453

				U.S. PATENT	DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)			entee or Applicant d Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
KKE	AA	4,513,006		Maryanoff et al	514 23	04/23/1985	
revet	AB	5,242,942		Costanzo et al	514   439	009/07/1993	
	AC	5,387,700		Maryanoff et al	549/387	02/07/1995	
KKF KKF	AD	6,071,537		Shank	424 / 464	06/06/2000	
KKEF	AE	6,191,163	B1	Cottrell	514 454	02/20/2001	
						·	
<del>-</del>				7-1-			

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite	Foreign Office <sup>3</sup>	Patent Document Number Patent		t dCode <sup>5</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
KKE	AF	wo	00/61139	7	A1	Ortho-McNeil Pharmaceutical, Inc.	10/19/2000		
KKF	AG	wo,	00/61140	J	A1	Ortho-McNeil Pharmaceutical, Inc.	10/19/2000		
KAF	AH	wo	99/44581	7	A2	Ortho-McNeil Pharmaceutical, Inc.	09/10/1999		<u> </u>
	AI	wor	00/50020	7	A2	University of Cincinnati	08/31/2000		
KAT	AS	wo)	00/76493	<b>√</b>	A1	Najarian	12/21/2000	-921	
	+			-					

Examiner	NW De Be-	Date	2-17-02	
Signature	CONSCI	Considered	312703	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PE C. WIR I THE PAPER WAR REDUCTION

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

pervolution Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form (1945)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	09/900.567
Filing Date	July 6, 2001
First Named Inventor	Plata-Salaman, C.
Group Art Unit	1614 1623
Examiner Name	Not yet assigned FONDA
Attorney Docket Number	ORT-1453

					U.S. PATENT DOCUMENTS	<del></del>		
		U.S. Patent Do			Name of Patentee or Applicant	Date of Publication		
Examiner	Cite	Cite Kind Code of Cited Doc		of Cited Document	of Cited Documer	nt where relevant pass or relevant figures a	ages	
Initials No.1		Number	(if	known)		mm-dd-yyyy	or relevant rigures a	ppear
							72	
							100	
						TECHCENTE	意の	
							- 1	
						7	1 4	
						?		
							8	
<u> </u>	<del>                                     </del>						3	
	<del>                                     </del>							
	<u> </u>							
								-
<del></del>	<u> </u>	<u> </u>	·	FORI	IGN PATENT DOCUMENTS			
	T	Foreign Paten	t Docume			Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office <sup>3</sup> Num	ıber⁴ Ki	ndCode⁵	Name of Patentee or Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁰
KOF	CA	WO 98/001	30	A2	Ortho Pharma Corp.	01-08-1998		
			<u> </u>					
	1							
	+	<del>                                     </del>						1

U.S. PATENT DOCUMENTS

Examiner Signature	22 Jonda	Date Considered	3-19-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

#### Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a	a vand UMB control number.
Application Number	09/900,567
Filing Date	July 6, 2001
First Named Inventor	Plata-Salaman, C.
Group Art Unit	1614 1623
Examiner Name	Not yet assigned For DA
Attorney Docket Number	ORT-1453

		NON SATENT LITERATURE COCUMENTS	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
EKF	CB.	YORK, D.A. et al.: "Effects of Topiramate on High Fat Diet-Induced Obesity". FASEB journal, Fed. Of America Soc. For Experimental Biology, Bethesda, MD, US., vol. 14, no.4, April 2000, page A431, XP000915192.	
·ince	CE/	The Merck Manual, 1999, Merck Research, Whitehouse Station, NJ, XP002224345, Diabetes Mellitus, pgs. 165-177.	
act-	CD/	EDWARDS, K.R. et al.: "Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a cyble-blind placebo -controlled study ADIS Title: Topiramate: therapeutic use; Neurogenic pain; In patients with diabetic perpethy Neurology 54 (Suppl. 3): 81,41, XP0080414165.	
		The state of the s	
ł	1		

Examiner Signature 220mla	Date Considered 3-19-03
---------------------------	-------------------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

# SUBMISSION UNDER MPEP 609 D Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

Page 1 of 1

Group Art Unit
Examiner Name
Not yet assigned
Attorney Docket Number

ORT-1453

09/900,567 July 6, 2001

Plata-Salaman, C.

		FOREIG	N PATENT	DOCUME	NTS		
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign P Office <sup>3</sup>	atent Docum	rent KindCode <sup>5</sup>	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		OTHER PRIOR ART. N	ON DATEN	LITEDATI	DE DOCUME	STC	
Examiner 's No.¹ Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
est-	PCT International Search Report, PCT/US01/21404, January 7, 2003.						
							<u> </u>

Date Considered

3-19-03

REONE

Examiner Signature